Analyst Ratings February 9, 2026

BMO Lifts Marathon Petroleum Price Target to $225, Citing Strong Refining Results

Analyst upgrades come after robust Q4 2025 results and upbeat 2026 guidance; midstream outlook trimmed slightly

By Ajmal Hussain MPC
BMO Lifts Marathon Petroleum Price Target to $225, Citing Strong Refining Results
MPC

BMO Capital raised its Marathon Petroleum (MPC) price target to $225.00 from $200.00 and kept an Outperform rating after the company reported stronger-than-expected fourth quarter 2025 results and provided optimistic first quarter 2026 guidance. The firm boosted 2026 and later EPS and EBITDA estimates, driven mainly by refining, while trimming its midstream EBITDA forecast marginally. Other analysts have also adjusted targets upward following the results.

Key Points

  • BMO Capital raised Marathon Petroleum’s price target to $225.00 from $200.00 and left an Outperform rating in place.
  • BMO increased 2026 EBITDA and cash flow from operations forecasts by 3% and 2% respectively, driven primarily by the refining segment.
  • Other brokers also boosted targets after the quarter - Wells Fargo to $217 (Overweight) and TD Cowen to $198 (Buy) - following Q4 2025 beats on EPS and revenue.

Overview

BMO Capital on Monday raised its price target for Marathon Petroleum (NYSE:MPC) to $225.00 from $200.00 and maintained an Outperform recommendation on the shares. At the time of the note, Marathon stock was trading at $203.71, narrowly below its 52-week high of $204.37, after a 14.75% gain over the prior week.

Results and guidance that moved the needle

The firm cited Marathon’s better-than-expected fourth quarter 2025 results and the company’s first quarter 2026 guidance as the drivers for the target increase. Marathon reported diluted earnings per share of $13.22 for the trailing twelve months, translating to a price-to-earnings ratio of 15.42 based on current pricing.

BMO adjusted its forward financial model upward, increasing 2026 and subsequent earnings per share and EBITDA forecasts. Specifically, the firm raised its 2026 EBITDA forecast by 3% and its forecast for cash flow from operations by 2%, attributing most of the lift to the refining segment.

At the same time, BMO trimmed its midstream EBITDA estimate by 1%. Despite that small reduction, the analyst note expressed continued support for MPLX’s project pipeline, which BMO says underpins an expected 5% EBITDA expansion and double-digit distribution growth for MPLX.

Valuation perspective and refining positioning

BMO’s sum-of-the-parts valuation for Marathon falls in a range near $215 to $235. The firm retained a constructive stance on the refining macro outlook and highlighted Marathon’s high-margin, advantaged refining footprint across the PADD 2, 3 and 5 regions as a competitive strength.

Market and peer reactions

Marathon’s fourth quarter of 2025 results were well ahead of consensus, with EPS of $4.07 versus the $3.01 estimate and revenue of $33.42 billion compared with an anticipated $32.86 billion. Following those results, other brokerages also revised their targets: Wells Fargo raised its price target to $217 and kept an Overweight rating, while TD Cowen increased its target to $198 and maintained a Buy rating, citing solid refining gross margin performance.


Contextual note

The combination of stronger-than-expected quarterly results, reinforced guidance and upward revisions to 2026 financial assumptions drove BMO’s decision to lift its price target, even as a modest adjustment was made to midstream expectations.

Risks

  • Midstream performance - BMO trimmed its midstream EBITDA estimate by 1%, indicating some downside risk in the midstream segment that could affect MPLX and related midstream valuations.
  • Valuation dispersion - BMO’s sum-of-the-parts valuation spans roughly $215 to $235, reflecting a range of potential outcomes for Marathon’s parts and introducing valuation uncertainty for investors.
  • Analyst divergence - Different broker targets (for example $217 from Wells Fargo and $198 from TD Cowen) show varied analyst views, which can lead to divergent market expectations and volatility.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026